Truist Securities analyst Robyn Karnauskas downgrades MEI Pharma (NASDAQ:MEIP) from Buy to Hold.
Truist Securities Downgrades MEI Pharma to Hold
Truist Securities analyst Robyn Karnauskas downgrades MEI Pharma (NASDAQ:MEIP) from Buy to Hold.
Related Posts
Vitalik Buterin Says Ethereum Will Process 100K Transactions Per Second After Merge
Ethereum (CRYPTO: ETH) will be far more scalable after the merge to a Proof-of-Stake network, according to the blockchain’s creator Vitalik Buterin.
Starbucks, Cisco And This Major Aircraft Manufacturer: CNBC’s ‘Final Trades’
On CNBC’s "Halftime Report Final Trades," Josh Brown of Ritholtz Wealth Management named Starbucks Corporation (NASDAQ: SBUX)
7 Analysts Have This to Say About YETI Holdings
YETI Holdings (NYSE:YETI) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…